Multi‐modal characterization of vasculature and nanoparticle accumulation in five tumor xenograft models
暂无分享,去创建一个
David J. Waxman | Catharina de Lange Davies | Steinar Lundgren | Sofie Snipstad | Sverre H. Torp | Annemieke van Wamel | Marius Widerøe | Igor Vidic | S. Lundgren | D. Waxman | S. Torp | C. de Lange Davies | A. van Wamel | Eugene Kim | Eugene Kim | E. Sulheim | Einar Sulheim | Jana Kim | Ingeborg Hovde Grimstad | Sofie Snipstad | Jana Kim | M. Widerøe | I. Vidić | I. Grimstad | A. V. van Wamel | Igor Vidić
[1] O. Haraldseth,et al. Periodicity in tumor vasculature targeting kinetics of ligand-functionalized nanoparticles studied by dynamic contrast enhanced magnetic resonance imaging and intravital microscopy , 2013, Angiogenesis.
[2] Benjamin M Yeh,et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Ashley M. Laughney,et al. Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle , 2015, Science Translational Medicine.
[4] T. B. Pedersen,et al. Assessment of early docetaxel response in an experimental model of human breast cancer using DCE‐MRI, ex vivo HR MAS, and in vivo 1H MRS , 2010, NMR in biomedicine.
[5] D. Jaffray,et al. Nanomedicine and tumor heterogeneity: Concept and complex reality , 2016 .
[6] Triantafyllos Stylianopoulos,et al. Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. , 2011, Annual review of chemical and biomolecular engineering.
[7] Amber L. Doiron,et al. Nanoparticle accumulation in angiogenic tissues: towards predictable pharmacokinetics. , 2013, Small.
[8] Brendan P. Flynn,et al. Nanoparticle uptake in tumors is mediated by the interplay of vascular and collagen density with interstitial pressure. , 2013, Nanomedicine : nanotechnology, biology, and medicine.
[9] F. Kiessling,et al. Characterizing EPR-mediated passive drug targeting using contrast-enhanced functional ultrasound imaging. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[10] Wenping Wang,et al. Early treatment response to sorafenib for rabbit VX2 orthotic liver tumors: evaluation by quantitative contrast-enhanced ultrasound , 2015, Tumor Biology.
[11] Michael Höpfner,et al. The shunt problem: control of functional shunting in normal and tumour vasculature , 2010, Nature Reviews Cancer.
[12] R. Jain,et al. Role of extracellular matrix assembly in interstitial transport in solid tumors. , 2000, Cancer research.
[13] R. Korn,et al. Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study , 2017, Clinical Cancer Research.
[14] H. Maeda,et al. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.
[15] R K Jain,et al. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. , 1990, Cancer research.
[16] S. Barry,et al. Tumour stromal morphology impacts nanomedicine cytotoxicity in patient-derived xenografts. , 2015, Nanomedicine : nanotechnology, biology, and medicine.
[17] Guido Gerig,et al. 3D Multi-scale line filter for segmentation and visualization of curvilinear structures in medical images , 1997, CVRMed.
[18] D. Crommelin,et al. Towards more effective advanced drug delivery systems. , 2013, International journal of pharmaceutics.
[19] M. Versluis,et al. Sonoprinting and the importance of microbubble loading for the ultrasound mediated cellular delivery of nanoparticles. , 2016, Biomaterials.
[20] Jennifer I. Hare,et al. Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. , 2017, Advanced drug delivery reviews.
[21] B. Johansen,et al. Anti‐angiogenic therapy affects the relationship between tumor vascular structure and function: A correlation study between micro–computed tomography angiography and dynamic contrast enhanced MRI , 2016, Magnetic resonance in medicine.
[22] D. Jaffray,et al. Tumor perfusion imaging predicts the intra-tumoral accumulation of liposomes. , 2013, Journal of controlled release : official journal of the Controlled Release Society.
[23] Ick Chan Kwon,et al. Real-time and non-invasive optical imaging of tumor-targeting glycol chitosan nanoparticles in various tumor models. , 2011, Biomaterials.
[24] T. Iwanaga,et al. Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. , 2001, Cancer research.
[25] A. Padhani,et al. Assessing changes in tumour vascular function using dynamic contrast‐enhanced magnetic resonance imaging , 2002, NMR in biomedicine.
[26] Zahi A. Fayad,et al. Nanoreporter PET predicts the efficacy of anti-cancer nanotherapy , 2016, Nature Communications.
[27] Ralph Weissleder,et al. Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug , 2015, Nature Communications.
[28] M. Knopp,et al. Estimating kinetic parameters from dynamic contrast‐enhanced t1‐weighted MRI of a diffusable tracer: Standardized quantities and symbols , 1999, Journal of magnetic resonance imaging : JMRI.
[29] C. de Lange Davies,et al. Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx™) in human osteosarcoma xenografts , 2005, British Journal of Cancer.
[30] G. Jensen,et al. Conventional Liposome Performance and Evaluation: Lessons from the Development of Vescan , 2007, Journal of liposome research.
[31] Andreas Kjær,et al. Positron Emission Tomography Based Elucidation of the Enhanced Permeability and Retention Effect in Dogs with Cancer Using Copper-64 Liposomes. , 2015, ACS nano.
[32] Joseph W. Nichols,et al. EPR: Evidence and fallacy. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[33] A. Giatromanolaki,et al. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] A. J. Tavares,et al. Analysis of nanoparticle delivery to tumours , 2016 .
[35] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[36] Johannes E. Schindelin,et al. The ImageJ ecosystem: An open platform for biomedical image analysis , 2015, Molecular reproduction and development.
[37] R. Jain,et al. Delivering nanomedicine to solid tumors , 2010, Nature Reviews Clinical Oncology.
[38] E. Barbier,et al. An MRI-based classification scheme to predict passive access of 5 to 50-nm large nanoparticles to tumors , 2016, Scientific Reports.
[39] M. Volm,et al. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. , 1996, British Journal of Cancer.
[40] P. Stattin,et al. Vascular density is a predictor of cancer‐specific survival in prostatic carcinoma , 1997, The Prostate.
[41] Karen Campbell,et al. 64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer , 2017, Clinical Cancer Research.
[42] Jan Grimm,et al. Nanoparticles for imaging: top or flop? , 2014, Radiology.
[43] R. Vile,et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[44] Fabian Kiessling,et al. Micro-CT Imaging of Tumor Angiogenesis Quantitative Measures Describing Micromorphology and Vascularization , 2014 .
[45] Kexiong Zhang,et al. Impact of Tumor Vascularity on Responsiveness to Antiangiogenesis in a Prostate Cancer Stem Cell-Derived Tumor Model , 2013, Molecular Cancer Therapeutics.
[46] P. Tofts. Modeling tracer kinetics in dynamic Gd‐DTPA MR imaging , 1997, Journal of magnetic resonance imaging : JMRI.
[47] Baris Turkbey,et al. Imaging of tumor angiogenesis: functional or targeted? , 2009, AJR. American journal of roentgenology.
[48] A. Brøgger,et al. Characteristics of a cell line established from a patient with multiple osteosarcoma, appearing 13 years after treatment for bilateral retinoblastoma , 1986, International journal of cancer.
[49] Jörg Huwyler,et al. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. , 2015, Journal of controlled release : official journal of the Controlled Release Society.
[50] N. Mitsakakis,et al. Spatial and temporal mapping of heterogeneity in liposome uptake and microvascular distribution in an orthotopic tumor xenograft model. , 2015, Journal of controlled release : official journal of the Controlled Release Society.
[51] Ming-Jium Shieh,et al. Combining the single-walled carbon nanotubes with low voltage electrical stimulation to improve accumulation of nanomedicines in tumor for effective cancer therapy. , 2016, Journal of controlled release : official journal of the Controlled Release Society.
[52] D. Le Bihan,et al. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. , 1988, Radiology.
[53] Hege Wergedahl,et al. Effect of dietary tetradecylthioacetic acid on colon cancer growth studied by dynamic contrast enhanced MRI , 2007, Cancer biology & therapy.
[54] G. Glover,et al. Breast disease: dynamic spiral MR imaging. , 1998, Radiology.
[55] Warren C W Chan,et al. Mediating tumor targeting efficiency of nanoparticles through design. , 2009, Nano letters.